[Research progress of exosomes in epithelial-mesenchymal transition].
epithelial-mesenchymal transition
exosomes
fibrosis
tumor
Journal
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
ISSN: 1673-4254
Titre abrégé: Nan Fang Yi Ke Da Xue Xue Bao
Pays: China
ID NLM: 101266132
Informations de publication
Date de publication:
30 Mar 2019
30 Mar 2019
Historique:
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
24
8
2019
Statut:
ppublish
Résumé
Exosome, a membranous vesicle with biological activity, not only transmits active substances between cells but also transfers information between cells to participate in cell communication. Epithelial-mesenchymal transition (EMT) is a process by which epithelial cells acquire migratory and invasive properties to become mesenchymal stem cells. EMT is essential for the development of a spectrum of diseases. Studies have shown that exosomes have dual effects on EMT to, on the one hand, promote EMT and tumor cell invasion and metastasis and accelerate angiogenesis and tumor growth; on the other hand, exosomes can suppress tumor cell invasion, inhibit fibrosis of the heart, liver and kidney, and improve myocardial infarction by inhibiting EMT. Exosomes modulate EMT-related signaling pathways by carrying EMT-related proteins or miRNA to exert their bi-directional regulatory effects.
Identifiants
pubmed: 31068312
doi: 10.12122/j.issn.1673-4254.2019.03.19
pmc: PMC6765673
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
chi
Pagination
377-380Références
Front Oncol. 2014 Dec 19;4:361
pubmed: 25566500
Cell Death Dis. 2018 May 3;9(5):513
pubmed: 29725020
Stem Cells Transl Med. 2017 Apr;6(4):1273-1285
pubmed: 28198592
Lung Cancer. 2016 Jul;97:87-94
pubmed: 27237033
J Immunol Methods. 2002 Dec 15;270(2):211-26
pubmed: 12379326
J Clin Med. 2016 Jul 14;5(7):
pubmed: 27429011
J Cell Physiol. 2019 Mar;234(3):2943-2953
pubmed: 30146796
Front Oncol. 2017 Aug 03;7:162
pubmed: 28824874
Curr Opin Cell Biol. 2009 Aug;21(4):575-81
pubmed: 19442504
Trends Pharmacol Sci. 2014 Sep;35(9):479-88
pubmed: 25042456
Pathol Oncol Res. 2018 Jan;24(1):11-18
pubmed: 28132116
EBioMedicine. 2018 Oct;36:209-220
pubmed: 30243489
Stem Cells Transl Med. 2016 Oct;5(10):1425-1439
pubmed: 27388239
Genes Dev. 2013 Oct 15;27(20):2192-206
pubmed: 24142872
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Oral Oncol. 2018 Nov;86:251-257
pubmed: 30409309
J Exp Clin Cancer Res. 2018 Mar 12;37(1):52
pubmed: 29530052
Cancer Sci. 2015 Dec;106(12):1669-77
pubmed: 26362844
Elife. 2015 Jul 01;4:e07197
pubmed: 26132860
Int J Cardiol. 2015 Oct 15;197:333-47
pubmed: 26159041
Oncogenesis. 2015 Aug 17;4:e163
pubmed: 26280654
Kidney Int. 2008 Dec;74(12):1526-37
pubmed: 18843253
Cancer Sci. 2014 Nov;105(11):1384-92
pubmed: 25220623
Proteomics. 2014 Mar;14(6):699-712
pubmed: 24376083
Oncotarget. 2018 Mar 27;9(23):16400-16417
pubmed: 29662654
Neoplasia. 2018 Aug;20(8):775-788
pubmed: 29981499
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Biochim Biophys Acta. 2012 Jul;1820(7):940-8
pubmed: 22503788
Biotechnol Adv. 2018 Jan - Feb;36(1):328-334
pubmed: 29248680
Oncotarget. 2017 Jun 20;8(25):41717-41733
pubmed: 28402944
Oncotarget. 2017 Mar 21;8(12):19592-19608
pubmed: 28121625
Circ Res. 2016 Dec 9;119(12):1280-1282
pubmed: 27932472
Curr Opin Cell Biol. 2016 Dec;43:7-13
pubmed: 27371787
BMC Cancer. 2014 Jan 27;14:44
pubmed: 24468161
Stem Cells Dev. 2013 Mar 15;22(6):845-54
pubmed: 23002959
Cell Physiol Biochem. 2015;37(6):2415-24
pubmed: 26646808
Oncotarget. 2016 Aug 23;7(34):54852-54866
pubmed: 27363026
Oncogene. 2014 Sep 11;33(37):4613-22
pubmed: 24662828
Biochem Biophys Res Commun. 2016 Sep 16;478(2):643-8
pubmed: 27492069
Cancer Lett. 2016 Jul 1;376(2):318-27
pubmed: 27063098